Clinical trials: Streptococcus Pneumoniae Vaccines
Streptococcus Pneumoniae Infection
Phase III Clinical Trial of 13-valent Pneumococcal Conjugate Vaccine (Multivalent Conjugate) in Infants
This study is a phase III clinical trial to evaluate the immunogenicity and safety of the 13-valent pneumococcal conjugate vaccine (multivalent conjugate) in infants aged 2 months (at least 6 weeks) and 3 months.
- Trial name
- NCT05759520
- Testing
- 13-valent pneumococcal conjugate vaccine (multivalent conjugate), Prevenar 13
- Where
- 5 sites in China
- Volunteers
- 1,800 people, healthy volunteers welcome
- Sponsor
- Fosun Adgenvax Biopharmaceutical Co.,Ltd.
Apnea, Apnea Neonatal
Apnea in Hospitalized Preterm Infants Following the Administration of Routine Childhood Vaccines
A prospective, randomized open-label clinical trial will be conducted from July 2018 to October 2020. Approximately 300 preterm infants will be enrolled across three sites: Duke University Medical Center, the University of North…
- Conditions
- Apnea, Apnea Neonatal, Prematurity
- Trial name
- NCT03530124
- Testing
- PCV13, DTaP, HBV
- Where
- 4 sites in United States
- Volunteers
- 223 people
- Sponsor
- Duke University
Pneumococcal Infections
Safety, Tolerability, and Immunogenicity of V114 Compared to Prevnar 13™ in PPSV23-vaccinated Healthy Adults ≥65 Years of Age (V114-007)
This study is designed to assess the safety, tolerability, and immunogenicity of V114 compared with Prevnar 13™ in healthy adults 65 years of age or older previously vaccinated with 23-valent pneumococcal polysaccharide vaccine.
- Trial name
- NCT02573181
- Testing
- V114, Prevnar 13™
- Volunteers
- 253 people, healthy volunteers welcome
- Sponsor
- Merck Sharp & Dohme LLC
Pneumococcal Infectious Diseases
Safety and Immunogenicity of a Newly 23-valent Pneumococcal Polysaccharide Vaccine in Chinese Adults and Children
A newly 23-valent pneumococcal polysaccharide vaccine was developed with promising safety and immunogenicity demonstrated in the phase III trial in China.
- Trial name
- NCT02285036
- Testing
- vaccination PPV23, vaccination PNEUMOVAX 23
- Where
- China
- Volunteers
- 1,660 people
- Sponsor
- Walvax Biotechnology Co., Ltd.
The Effect of Milk Components on the Response to Pneumococcal Vaccines in the Elderly
The Effect of Milk Components on the Response to the Pneumonia Vaccine in Senior Citizens
The purpose of this study is to determine if the daily use of a certain amount and type of milk component for 2 months provides a significant stimulation to the immune system and specifically increases the chances of being…
- Trial name
- NCT01626300
- Volunteers
- 45 people, healthy volunteers welcome
- Sponsor
- University of California, Davis
Healthy Subjects
A Trial Evaluating a 7-valent Pneumococcal Conjugate Vaccine Given With Diphtheria, Tetanus, and Acellular Pertussis Vaccine (DTaP) in Healthy Japanese Infants.
Subjects will be randomly assigned to 1 of 2 groups to receive the following vaccines: Group 1: 7-valent pneumococcal conjugate vaccine (7vPnC) and diphtheria, tetanus, and accelular pertussis vaccine (DTaP), Group 2: DTaP alone.
- Trial name
- NCT01250756
- Testing
- 7-pneumococcal conjugate vaccine (7vPnC), diphtheria, tetanus, and acellular pertussis vaccine (DTaP), DTaP
- Where
- 18 sites in Japan
- Volunteers
- 321 people, healthy volunteers welcome
- Sponsor
- Pfizer
Influenza, Human, Pneumonia, Pneumococcal
Evaluation of Safety and Immunogenicity of Combined Immunization of PPV23 and IIV4
Subjects will be recruited and divided into 3 groups: 1. Experimental Group (408 subjects): combined immunization of PPV23 and IIV4; 2. Control Group A (408 subjects): IIV4 only; 3.
- Trial name
- NCT04559204
- Testing
- IIV4 and PPV23, IIV4, PPV23
- Where
- 4 sites in China
- Volunteers
- 1,224 people, healthy volunteers welcome
- Sponsor
- China National Biotec Group Company Limited
Pneumococcal Vaccine
Assessment of Knowledge on Pneumococcal Vaccination Among Diabetologists in India
Asia has the highest burden with the largest contribution of pneumonia burden from India. Pneumonia is also observed as 5th leading cause of deaths in India.
- Trial name
- NCT05721092
- Testing
- Pre and Post Education on practice of pneumococcal vaccination
- Where
- India
- Volunteers
- 100 people, healthy volunteers welcome
- Sponsor
- M.V. Hospital for Diabetes
Pneumococcal Infections
Trial to Evaluate the Safety and Immunogenicity of Multivalent Pneumococcal Vaccines in Japanese Adults 18 to 49 Years of Age
This Phase 1b will describe the safety and immunogenicity of 2 multivalent pneumococcal conjugate vaccine formulations in healthy Japanese adults in the United States.
- Trial name
- NCT03642847
- Testing
- Prevnar 13, multivalent pneumococcal conjugate formulation 1, multivalent pneumococcal conjugate formulation 2
- Where
- 4 sites in United States
- Volunteers
- 104 people, healthy volunteers welcome
- Sponsor
- Pfizer
Pneumococcal Disease
Safety Surveillance of Pneumococcal 13-valent Conjugate Vaccine Among Filipinos
Prevenar 13 is safe for administration to Filipinos.
- Trial name
- NCT01396434
- Testing
- Prevenar 13
- Where
- 119 sites in Philippines
- Volunteers
- 3,006 people, healthy volunteers welcome
- Sponsor
- Pfizer
Pneumonia, Respiratory Tract Diseases
Clinical Trial of Recombinant Pneumococcal Protein Vaccine
Streptococcus pneumoniae infections often cause serious health problems, especially in infants and the elderly. Failure to cover all polysaccharide types of vaccines is a greater problem for adults than for children.
- Conditions
- Pneumonia, Respiratory Tract Diseases, Respiratory Tract Infections
- Trial name
- NCT05622942
- Testing
- PBPV, PPV23
- Where
- China
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- CanSino Biologics Inc.
Pneumonia, Meningitis
Persistence of Immunogenicity Following Reduced PCV Dosing Schedules in South African Children
This study will evaluate the persistence of immunogenicity following a reduced dosing schedule of 10- or 13-valent Pneumococcal Conjugate Vaccine (PCV10, PCV13).
- Trial name
- PCV1+1_FU (NCT04275284)
- Testing
- PCV10, PCV13
- Where
- South Africa
- Volunteers
- 600 people
- Sponsor
- University of Witwatersrand, South Africa
Acute Febrile Illness, Pneumococcal Infections
Immunogenicity and Safety PCV-20 of the Vaccine Administered During an Acute Febrile Illness in Adults
Streptococcus pneumoniae is responsible for serious infections associated to numerous hospitalizations and high rate of mortality.
- Trial name
- PREV-HOSPIT (NCT06822907)
- Testing
- Early intervention, Delayed intervention
- Where
- 24 sites in France
- Volunteers
- 1,052 people
- Sponsor
- Centre Hospitalier Universitaire de Saint Etienne
Pneumococcal Vaccines, HIV
Conjugate And Polysaccharide Vaccines Compared With Polysaccharide Vaccine In Hiv-Infected Adults
Randomised study comparing two pneumococcal vaccination strategies in HIV-infected adults with moderate immunossupression (CD4 between 200 and 500 cells/uL and viral load under 5logs), one with conjugated heptavalent…
- Conditions
- Pneumococcal Vaccines, HIV, HIV Infections
- Trial name
- NCT00999739
- Testing
- Prevenar and Pneumo23
- Where
- 2 sites in Spain
- Volunteers
- 220 people
- Sponsor
- Hospital Universitari Son Dureta
Infections, Streptococcal
Safety and Immunogenicity Study of GlaxoSmithKline (GSK) Biologicals' Pneumococcal Vaccine 2830930A Administered in Toddlers
The purpose of this study is to assess the safety, reactogenicity and immunogenicity of the GSK Biologicals' pneumococcal vaccine 2830930A in toddlers aged 12 to 23 months at study entry.
- Trial name
- NCT01485406
- Testing
- Pneumococcal vaccine GSK2830930A, Synflorix™
- Where
- 4 sites in Germany
- Volunteers
- 61 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Infections, Streptococcal
Long-term Follow-up Study of Children Previously Primed With GSK Pneumococcal Vaccine (GSK1024850A) and of Unprimed Children
The objective of this study is to evaluate the immune memory through the administration of an additional dose of GSK Biologicals' pneumococcal conjugate vaccine GSK1024850A, the antibody persistence and long-term effect on…
- Trial name
- NCT00950833
- Testing
- Pneumococcal vaccine GSK1024850A
- Where
- 10 sites in Czechia
- Volunteers
- 466 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
HIV-1-infection, Human Immunodeficiency Virus
Impact of HIV-1 and Aging on Mucosal Vaccine Responses
The purpose of this study is to learn more about both HIV-1 infection and advancing age, and their association with increased risk of serious infection and impaired response to the Prevnar 13 vaccine.
- Conditions
- HIV-1-infection, Human Immunodeficiency Virus, HIV/AIDS, HIV Infections
- Trial name
- NCT03729778
- Testing
- Prevnar-13
- Where
- United States
- Volunteers
- 100 people, healthy volunteers welcome
- Sponsor
- VA Eastern Colorado Health Care System
Pneumococcal Infections, Streptococcal Infections
A Clinical Trial of the 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (CRM197/Tetanus Toxoid)
This clinical study will enroll 100 participants from the 2-month-old (minimum 6 weeks) group who previously participated in the Phase III clinical trial of the 13-valent pneumococcal polysaccharide conjugate vaccine (CRM197, TT…
- Conditions
- Pneumococcal Infections, Streptococcal Infections, Bacterial Infections
- Trial name
- NCT07648641
- Testing
- Previously vaccinated with PCV13 (CanSino), Previously vaccinated with PCV13 (Pfizer)
- Volunteers
- 100 people, healthy volunteers welcome
- Sponsor
- CanSino Biologics Inc.
Healthy
Study Evaluating 13-valent Pneumococcal Conjugate Vaccine in Healthy Japanese Adults Aged >= 50 Years
The purpose of this study is to evaluate the safety, tolerability, and immunogenicity of the 13-valent pneumococcal conjugate (13vPnC) vaccine in healthy Japanese adults aged >= 50 years.
- Trial name
- NCT00562354
- Testing
- 13vPnC
- Where
- 2 sites in Japan
- Volunteers
- 271 people, healthy volunteers welcome
- Sponsor
- Pfizer
Pneumococcal Infections
Trial to Evaluate the Safety and Immunogenicity of a Multivalent Pneumococcal Conjugate Vaccine in Adults 60 Through 64 Years of Age
This is a Phase 2, randomized, double-blinded study with a 2-arm parallel design. Healthy adults aged 60 through 64 years of age with no history of pneumococcal vaccination will be randomized equally to receive either a single…
- Trial name
- NCT03313037
- Testing
- Multivalent, Prevnar 13, PPSV23
- Where
- 14 sites in United States
- Volunteers
- 444 people, healthy volunteers welcome
- Sponsor
- Pfizer